Literature DB >> 19546404

Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.

Remi A Nout1, Hein Putter, Ina M Jürgenliemk-Schulz, Jan J Jobsen, Ludy C H W Lutgens, Elzbieta M van der Steen-Banasik, Jan Willem M Mens, Annerie Slot, Marika C Stenfert Kroese, Bart N F M van Bunningen, Vincent T H B M Smit, Hans W Nijman, Philine P van den Tol, Carien L Creutzberg.   

Abstract

PURPOSE Studies on quality of life (QOL) among women with endometrial cancer have shown that patients who undergo pelvic radiotherapy report lower role functioning and more diarrhea and fatigue. In the Post Operative Radiation Therapy in Endometrial Cancer (PORTEC) trial, patients with endometrial carcinoma were randomly assigned to receive external-beam radiotherapy (EBRT) or vaginal brachytherapy (VBT). QOL was evaluated by using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and subscales from the prostate cancer module, PR-25, and the ovarian cancer module, OV-28. PATIENTS AND METHODS PORTEC-2 accrued 427 patients between 2002 and 2006, of whom 214 were randomly assigned to EBRT, and 213 were randomly assigned to VBT. Three-hundred forty-eight patients (81%) were evaluable for QOL. QOL outcomes were analyzed at a median follow-up of 2 years. Results At baseline after surgery, patient functioning was at the lowest level, and it increased during and after radiotherapy to reach a plateau after 12 months. Patients in the VBT group reported better social functioning (P < .002) and lower symptom scores for diarrhea, fecal leakage, the need to stay close to the toilet, and limitation in daily activities because of bowel symptoms (P < .001). At baseline, 15% of patients were sexually active; this increased significantly to 39% during the first year (P < .001). Sexual functioning and symptoms did not differ between the treatment groups. CONCLUSION Patients who received EBRT reported significantly higher levels of diarrhea and bowel symptoms. This resulted in a higher need to remain close to a toilet and, as a consequence, more limitation of daily activities because of bowel symptoms and decreased social functioning. Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective.

Entities:  

Mesh:

Year:  2009        PMID: 19546404     DOI: 10.1200/JCO.2008.20.2424

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  63 in total

1.  Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy.

Authors:  S Sabater; Ma M Sevillano; I Andres; R Berenguer; S Machin-Hamalainen; K Müller; M Arenas
Journal:  Strahlenther Onkol       Date:  2013-09-04       Impact factor: 3.621

2.  Vaginal brachytherapy for endometrial cancer.

Authors:  Peter Hass; Selvi Seinsch; Holm Eggemann; Tanja Ignatov; Stephan Seitz; Atanas Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-05       Impact factor: 4.553

3.  Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical Cancer.

Authors:  Aparna Mitra; Greyson Willis Grossman Biegert; Andrea Y Delgado; Tatiana V Karpinets; Travis N Solley; Melissa P Mezzari; Kyoko Yoshida-Court; Joe F Petrosino; Megan D Mikkelson; Lilie Lin; Patricia Eifel; Jianhua Zhang; Lois M Ramondetta; Anuja Jhingran; Travis T Sims; Kathleen Schmeler; Pablo Okhuysen; Lauren E Colbert; Ann H Klopp
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-01-25       Impact factor: 7.038

4.  Concomitant endometrial and pancreatic cancers.

Authors:  S Michelle Shiller; Shawna L Bull Phelps; Jeffrey P Lamont; Granger R Scruggs
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-04

5.  Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.

Authors:  Gunjal Garg; Cecilia Yee; Kendra Schwartz; David G Mutch; Robert T Morris; Matthew A Powell
Journal:  Gynecol Oncol       Date:  2014-02-19       Impact factor: 5.482

6.  Rectal bleeding after radiation therapy for endometrial cancer.

Authors:  Devarati Mitra; Remi Nout; Paul J Catalano; Carien Creutzberg; Nicole Cimbak; Larissa Lee; Akila N Viswanathan
Journal:  Radiother Oncol       Date:  2015-05-20       Impact factor: 6.280

Review 7.  Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?

Authors:  S Marnitz; C Köhler; N Gharbi; S Kunze; K Jablonska; J Herter
Journal:  Strahlenther Onkol       Date:  2018-08-15       Impact factor: 3.621

8.  Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006.

Authors:  Marco Johannes Battista; Marcus Schmidt; Nicole Rieks; Isabel Sicking; Stefan Albrich; Michael Eichbaum; Heinz Koelbl; Peter Mallmann; Gerald Hoffmann; Eric Steiner
Journal:  J Cancer Res Clin Oncol       Date:  2014-09-26       Impact factor: 4.553

9.  Controversies in the management of endometrial carcinoma.

Authors:  Ying Zhang; Jian Wang
Journal:  Obstet Gynecol Int       Date:  2010-06-22

10.  Use of electronic brachytherapy to deliver postsurgical adjuvant radiation therapy for endometrial cancer: a retrospective multicenter study.

Authors:  William C Dooley; John P Thropay; Gary J Schreiber; Mohamed Y Puthawala; Steven C Lane; James C Wurzer; Charles E Stewart; Gordon L Grado; Harish G Ahuja; Gary M Proulx
Journal:  Onco Targets Ther       Date:  2010-10-05       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.